PLK1 and pancreatic ductal adenocarcinoma: Another study demonstrated that inhibiting PLK1 led to the upregulation of PD-L1 expression in pancreatic ductal adenocarcinoma, which enhanced anti-tumor immunity and increased tumor sensitivity to immunotherapy [64].